Two studies investigated the use of Bevacizumab (targeting the vascular endothelial growth factor α, VEGF-α) bound to either IRDye800CW or 800CW in the identification of primary breast cancer and locally advanced rectal cancer, respectively. Here, VEGFA is linked to breast cancer.